164 related articles for article (PubMed ID: 35898161)
21. Coamplification of 12q15 and 12p13 and homozygous CDKN2A/2B deletion: synergistic role of fibrosarcomatous transformation in dermatofibrosarcoma protuberans with a cryptic COL1A1-PDGFB fusion.
Lu Y; Li T; Chen M; Peng H; Du T; Qiu Y; Zhang H
Virchows Arch; 2022 Aug; 481(2):313-319. PubMed ID: 35171326
[TBL] [Abstract][Full Text] [Related]
22. A systematic review of outcome data for dermatofibrosarcoma protuberans with and without fibrosarcomatous change.
Liang CA; Jambusaria-Pahlajani A; Karia PS; Elenitsas R; Zhang PD; Schmults CD
J Am Acad Dermatol; 2014 Oct; 71(4):781-6. PubMed ID: 24755121
[TBL] [Abstract][Full Text] [Related]
23. PDGFB Rearrangements in Dermatofibrosarcoma Protuberans of the Vulva: A Study of 11 Cases Including Myxoid and Fibrosarcomatous Variants.
Jahanseir K; Xing D; Greipp PT; Sukov WR; Keeney GL; Howitt BE; Schoolmeester JK
Int J Gynecol Pathol; 2018 Nov; 37(6):537-546. PubMed ID: 29140881
[TBL] [Abstract][Full Text] [Related]
24. COL1A1-PDGFB fusion transcripts in fibrosarcomatous areas of six dermatofibrosarcomas protuberans.
Wang J; Morimitsu Y; Okamoto S; Hisaoka M; Ishida T; Sheng W; Hashimoto H
J Mol Diagn; 2000 Feb; 2(1):47-52. PubMed ID: 11272901
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of Imatinib Mesylate Treatment in a Patient with Dermatofibrosarcoma Protuberans with Pulmonary and Pancreatic Metastases.
Tatai T; Gomi D; Fukushima T; Kobayashi T; Sekiguchi N; Sakamoto A; Sasaki S; Koizumi T; Sano K
Intern Med; 2016; 55(17):2507-11. PubMed ID: 27580559
[TBL] [Abstract][Full Text] [Related]
26. Dermatofibrosarcoma protuberans: A retrospective study of clinicopathologic features and related Akt/mTOR, STAT3, ERK, cyclin D1, and PD-L1 expression.
Park S; Cho S; Kim M; Park JU; Jeong EC; Choi E; Park JH; Lee C; Chang MS
J Am Acad Dermatol; 2018 Nov; 79(5):843-852. PubMed ID: 29792909
[TBL] [Abstract][Full Text] [Related]
27. Dermatofibrosarcoma Protuberans.
Allen A; Ahn C; Sangüeza OP
Dermatol Clin; 2019 Oct; 37(4):483-488. PubMed ID: 31466588
[TBL] [Abstract][Full Text] [Related]
28. Metastatic potential of dermatofibrosarcoma protuberans with fibrosarcomatous change.
Minter RM; Reith JD; Hochwald SN
J Surg Oncol; 2003 Mar; 82(3):201-8. PubMed ID: 12619065
[TBL] [Abstract][Full Text] [Related]
29. From Morphea to Dermatofibrosarcoma Protuberans.
Crnarić I; Šitum M; Delaš Aždajić M; Vučić M; Buljan M
Acta Dermatovenerol Croat; 2022 Sep; 30(2):113-115. PubMed ID: 36254545
[TBL] [Abstract][Full Text] [Related]
30. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.
McArthur GA; Demetri GD; van Oosterom A; Heinrich MC; Debiec-Rychter M; Corless CL; Nikolova Z; Dimitrijevic S; Fletcher JA
J Clin Oncol; 2005 Feb; 23(4):866-73. PubMed ID: 15681532
[TBL] [Abstract][Full Text] [Related]
31. The prognostic significance of fibrosarcomatous transformation in dermatofibrosarcoma protuberans.
Abbott JJ; Oliveira AM; Nascimento AG
Am J Surg Pathol; 2006 Apr; 30(4):436-43. PubMed ID: 16625088
[TBL] [Abstract][Full Text] [Related]
32. Risk factors for distant metastasis of dermatofibrosarcoma protuberans.
Hayakawa K; Matsumoto S; Ae K; Tanizawa T; Gokita T; Funauchi Y; Motoi N
J Orthop Traumatol; 2016 Sep; 17(3):261-6. PubMed ID: 27289468
[TBL] [Abstract][Full Text] [Related]
33. Analysis of gene mutations in three cases of dermatofibrosarcoma protuberans (DFSP): ordinary DFSP, DFSP with fibrosarcomatous lesion (DFSP-FS) and lung metastasis of DFSP-FS.
Saeki H; Hoashi T; Tada Y; Ashida R; Kuwano Y; Le Pavoux A; Tsunemi Y; Shikada J; Torii H; Kawabata Y; Kikuchi K; Tamada Y; Matsumoto Y; Tamaki K
J Dermatol Sci; 2003 Dec; 33(3):161-7. PubMed ID: 14643521
[TBL] [Abstract][Full Text] [Related]
34. Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate.
Labropoulos SV; Fletcher JA; Oliveira AM; Papadopoulos S; Razis ED
Anticancer Drugs; 2005 Apr; 16(4):461-6. PubMed ID: 15746584
[TBL] [Abstract][Full Text] [Related]
35. Targeted therapy for dermatofibrosarcoma protuberans.
Abrams TA; Schuetze SM
Curr Oncol Rep; 2006 Jul; 8(4):291-6. PubMed ID: 17254529
[TBL] [Abstract][Full Text] [Related]
36. Review of dermatofibrosarcoma protuberans.
Lim SX; Ramaiya A; Levell NJ; Venables ZC
Clin Exp Dermatol; 2023 Mar; 48(4):297-302. PubMed ID: 36630365
[TBL] [Abstract][Full Text] [Related]
37. Myoid differentiation and EMA expression in fibrosarcomatous dermatofibrosarcoma protuberans.
Arican O; Bakaris S; Bulbuloglu E; Ezberci F
Acta Dermatovenerol Alp Pannonica Adriat; 2006 Mar; 15(1):39-44. PubMed ID: 16850098
[TBL] [Abstract][Full Text] [Related]
38. [Dermatofibrosarcoma protuberans].
Sanmartín O; Llombart B; López-Guerrero JA; Serra C; Requena C; Guillén C
Actas Dermosifiliogr; 2007 Mar; 98(2):77-87. PubMed ID: 17397592
[TBL] [Abstract][Full Text] [Related]
39. A case report of abdominal metastatic dermatofibrosarcoma protuberans misdiagnosed as gastrointestinal stromal tumor.
Deng M; Liu Q; Ren L; Yuan W; Xu C; Hou Y
Diagn Pathol; 2024 Feb; 19(1):41. PubMed ID: 38388419
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathological features of fibrosarcomatous dermatofibrosarcoma protuberans and the construction of a back-propagation neural network recognition model.
Li Y; Liang J; Xu X; Jiang X; Wang C; Chen S; Xiang B; Ji Y
Orphanet J Rare Dis; 2021 Jan; 16(1):48. PubMed ID: 33499900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
